Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
ImmunityBio merger with NantKwest
Davis Polk is advising Goldman Sachs & Co. LLC and Lazard Frères & Co. LLC as financial advisers to ImmunityBio, Inc…
Solid Biosciences $90 million common stock PIPE offering
Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Solid…
Atara Biotherapeutics $175 million common stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a…
Seer $336 million IPO and concurrent private placement
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 10,592…
Oak Street Health $297.9 million secondary offering
Davis Polk advised the joint book-running managers in connection with the $297.9 million secondary offering of 6,477…
BeiGene $340 million secondary offering
Davis Polk advised the underwriter in connection with the $340 million SEC-registered offering of 1,511,546 American…
Notre Dame Intermédica R$3.8 billion equity offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Bain Capital, the…
RAPT Therapeutics $100 million at-the-market offering
Davis Polk advised the sales agents on the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its…
Revance Therapeutics $125 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Revance Therapeutics, Inc. of its…
Esperion Therapeutics $250 million convertible senior subordinated notes
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Esperion…